key: cord-0743789-patq6nmw
authors: Pastor‐Nieto, MA; Checa‐Díaz, P; González‐Muñoz, P; Martín‐Fuentes, A; Vergara‐Sánchez, A; Sánchez‐Herreros, C; Jiménez‐Blázquez, E; Cabana‐Navia, R; Martínez‐Mariscal, J; Cobo‐Rodríguez, Pablo; Checa‐Recio, Iván; Gatica‐Ortega, ME; Torralba, M; De Eusebio‐Murillo, E
title: Prior treatment with immunosuppressants among COVID‐19 inpatients at one hospital in Spain
date: 2020-06-28
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.16798
sha: 369bac21ab0e3e14ccf8f5543e6a9e50bec836c7
doc_id: 743789
cord_uid: patq6nmw

Vulnerability to coronavirus disease 2019 (COVID‐19) in patients with cardiovascular risk factors is well known. However, the prognostic influence of immunosuppressive drugs or their ability to counteract the cytokine storm involving critically‐ill patients are uncertain. The scarce related literature mainly involves transplantation.

relationships between themselves or others that might be perceived by others as biasing their work. On behalf of all co-authors, the corresponding author uploaded the electronically completed ICMJE COI Disclosure Statements forms for each author and herself.

Ethics. Written informed consent was waived in light of the urgent need to collect data.

Authorship. All persons designated as authors qualify for authorship and all those who qualify are listed.

This article is protected by copyright. All rights reserved Vulnerability to coronavirus disease 2019 (COVID-19) in patients with cardiovascular risk factors is well known. However, the prognostic influence of immunosuppressive drugs or their ability to counteract the cytokine storm involving critically-ill patients are uncertain.

The scarce related literature mainly involves transplantation 1-3 .

Dermatologists routinely deal with patients receiving immunosuppressants and evidencebased-protocols on how to proceed under the pandemic are lacking.

We evaluated patients hospitalized with COVID-19 in the University Hospital of 

This article is protected by copyright. All rights reserved rheumatica; azathioprine plus prednisone for autoimmune hepatitis (1) and tacrolimus plus everolimus plus prednisone for lung transplant (1).

All immunosuppressed patients had comorbidities such as: hypertension (17; 60.7%); hyperlipidemia (12, 42.8%); diabetes mellitus (9, 32%); cancer (5, 17.8%); or hypothyroidism (5, 17.8%). Fatalities during hospitalization involved 69 nonimmunosuppressed (17%) and 7 immunosuppressed (25%) patients.

Treatment with immunosuppressants prior to hospitalization (OR 1.67 95%CI 0.67-4.0; p=0.278) or being male (OR 1.28 95%CI: 0.75-2.16; p=0.367) did not increase the mortality risk of COVID-19. On the other hand, the older the patient was, the higher the mortality risk. On average, the patients who died were older (mean age: 76.6 years) than the patients who survived (mean age: 65.7 years) (mean difference 10.97 95%CI 7.86-14.08; p<0.001). Multivariate logistic regression analysis was applied to determine the effect of immunosuppression on mortality adjusted by age and sex and no increase in the mortality within immunosuppressed patients was observed either (OR 1.14 95%CI 0.45-2.90; p= 0.784).

To conclude, we unanticipatedly found a low proportion of patients with prior immunosuppressive therapy, did not observe any patients taking biologics and could not find significant differences in mortality rates with regards to prior treatment with immunosuppressants among COVID-19 inpatients. Whether immunosuppressed patients are taking extra precautions or interrupting the treatments and how this may impact our results is unknown. On the other hand, this research further suggests the impact of advanced age in the outcome of COVID-19 inpatients since individuals who are at an advanced age have a lower survival rate. Our research represents a preliminary approach and hopefully may boost further larger studies. The need for evidence is urgent in order to create protocols guiding our practice under the current emergency circumstances.

Coronaviruses and immunosuppressed patients. The facts during the third epidemic

Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression

Coronavirus Disease 2019 and Transplantation: a view from the inside

Sitio Oficial del Departamento de Seguridad Nacional

Actualizado a 27 de marzo

Accepted Article